Dr. Sunil Kumar Dubey

Dr. Sunil Kumar Dubey is presently working as Senior General Manager (Head) Medical Research at Emami Ltd, Kolkata. He is involved in planning and ensuring the timely execution of several preclinical and clinical studies. His expertise involves validating the effectiveness of a vast range of healthcare products and providing business development-related insights. He is responsible for developing product concept notes, technical notes, monographs, and dossiers. His team is also involved in supporting medico-marketing, product licensing activities, and training personnel from marketing and sales teams. Collectively, his efforts are towards bridging the gap between the industry, consumers, and the scientific community. He has completed various government and industry-funded projects related to new product development, alongside PK/PD investigations. All these concerted efforts have led to the grant of patents to his name as well. He has extensive research experience in the area of PK/PD modeling and simulations, the development of phytopharmaceuticals, and numerous nano-technology-based drug delivery platforms. He is proficient in regulatory affairs, adeptly navigating guidelines established by various regulatory agencies. He has over 18 years of industrial, teaching, research, and administrative experience. He was also a visiting Assistant Research Professor in the Department of Chemical and Bio-molecular Engineering at the University of Maryland, USA. He also serves as a guest faculty at various leading institutes including NIPER Guwahati, NIPER Raebareli, Jamia Hamdard, and IIT Dhanbad. He has patents and has published over 185 articles, books, and book chapters in renowned high-impact journals and presented papers at conferences in India and abroad. He is included in the list of ‘World’s Top 2% Most-Cited Scientists’ as per the Elsevier-Stanford University report. Research Area: Formulation Development and Pharmacokinetic Pharmacodynamic (PK/PD) Modelling and Simulation Photodynamic Therapy: Fabrication of a novel lipid-polymer hybrid nanoparticles for targeted drug delivery. These nanoparticles include at least one therapeutic agent or siRNA and a photosensitizer. Upon a targeted application of light in the near infrared range, these nanoparticles disrupt and release the therapeutic agent at a specific site. Pharmacokinetics/ Pharmacodynamics of Phytopharmaceuticals for Metabolic Disorders: Understanding PK/PD of active constituents present in the enriched extract is of utmost importance for getting regulatory approvals.